• Do this before the bubble bursts

    Image of robot blowing bubble with AIs in it.

    “Is this an AI bubble?”

    It’s a question being asked more frequently as share prices rise, optimism grows and investors become increasingly excited about artificial intelligence.

    And fair enough, too.

    We’ve seen this movie before. A genuinely transformative technology appears. Investors imagine the possibilities. Capital pours in. Share prices rise. And, eventually, enthusiasm gets ahead of reality.

    The dot-com boom is the obvious comparison. The internet really did change the world, just as its champions predicted. But that didn’t stop investors losing fortunes when the bubble burst.

    So, is history repeating?

    Maybe.

    But maybe not.

    There’s no rule that says rapidly rising share prices must fall. Nor that excitement must end in disaster. Sometimes businesses grow into apparently expensive valuations. Sometimes the optimists are right.

    And AI is already producing real products, real revenue and real productivity gains. Some of today’s leading companies are immensely profitable, rather than hopeful start-ups with little more than a web address and a breathless business plan.

    That doesn’t mean their shares are cheap. It doesn’t mean every AI-related investment will succeed. And it certainly doesn’t mean prices can’t fall.

    It simply means we should resist the temptation to confidently predict what happens next.

    (It’s possible AI continues its rise, and the losers are those businesses most exposed to that disruption!)

    A better approach?

    Prepare, don’t predict.

    Use today’s enthusiasm – and the possibility that it ends – as a prompt to check what you actually own.

    Not just AI, though.

    Everything.

    Because tough times tend to reveal what the good times hide.

    When share prices are climbing, almost every investment seems smart. The ‘rising tide lifts all boats’.

    (That phrase apparently goes back at least to the 1600s – a reminder that while technology advances, there really is nothing new under the sun!)

    It’s easy to get caught up in the story… and to convince ourselves that it’s skill, not luck.

    It’s only when conditions change that the differences become obvious.

    Consider retail.

    A good retailer can have a tough year. We might reduce our spending and costs might rise. 

    As a result, sales can slow and profits can fall.

    But short-term troubles don’t necessarily make it a bad business.

    The important questions are whether customers still value what it sells, whether it is taking or losing market share, whether its stores remain productive and whether management can sensibly navigate the downturn.

    Because a healthy retailer can emerge from a difficult period in a stronger competitive position, particularly if weaker rivals close stores, cut investment or… disappear altogether.

    A structurally challenged retailer is different, of course. Customers may not want its products, or might prefer shopping at the competition. Margins might be permanently shrinking. A cyclical recovery won’t necessarily rescue a business whose competitive position has deteriorated.

    Here’s the thing: the share price might fall in both cases. But they’re not the same business.

    Your job is to know which one you own.

    Then there’s debt.

    Borrowing can make a good business look even better when times are favourable. It can fund expansion, lift margins and improve returns on equity. Things that are otherwise hallmarks of a successful business.

    But banks don’t care whether the economy is strong or weak. The interest bill still needs to be paid. Loans still need to be refinanced.

    And lenders tend to be least generous when borrowers need them most.

    That’s when the difference between a strong balance sheet and a fragile one becomes painfully clear.

    A financially strong company can keep investing through a downturn. It might acquire a competitor, open new locations or buy back shares at attractive prices.

    A heavily indebted company usually doesn’t have those choices. It can be forced to cut investment, sell assets, sack staff, or raise capital at exactly the wrong time.

    We learned that during COVID.

    The time to think about these things is before things get messy.

    What things? Ask yourself some of these questions:

    Does the company generate positive cash flow?

    Does it earn attractive returns on capital?

    Does it have a strong balance sheet?

    Do customers genuinely value its products?

    Does it have an advantage competitors will struggle to copy or beat?

    And does it have room to grow?

    Then consider what you’re paying. A wonderful business can still be a poor investment if its share price assumes everything will go perfectly.

    The thing is, those fundamentals don’t seem to matter when prices are rising. They get ignored when everyone is focused on growth, and optimism, and when ‘what can go wrong?’ is a rhetorical question, not a real one.

    And then… things go wrong.

    The economy stutters. Rates go up. Investors get nervous. Prices fall.

    It can be hard to remember that when the highly leveraged, high risk companies are flying high. 

    It can be tempting to abandon disciplined investing and join the party.

    Until the music stops.

    And when it does, it’ll be too late to realise you own a collection of exciting stories, ephemeral profits, overleveraged balance sheets, and ‘hopes and dreams’.

    You’ll realise you should have prioritised quality and value over high-risk and high hopes.

    No-one can know what will happen, when. 

    No-one.

    And when you really understand that, you stop playing Russian roulette.

    You make sure you’re prepared.

    The time to make sure? Before the bad times come.

    When will that be? No-one knows.

    That’s why you should be prepared.

    Fool on!

    The post Do this before the bubble bursts appeared first on The Motley Fool Australia.

    Wondering where you should invest $1,000 right now?

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes could be the ‘five best ASX stocks’ for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now…

    * Returns as of 1 August 2026

    .custom-cta-button p {
    margin-bottom: 0 !important;
    }

    More reading

    Motley Fool contributor Scott Phillips has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

  • Are Telix shares a buy after its big US FDA news?

    Male and female scientists analysing data on a computer.

    Telix Pharmaceuticals Ltd (ASX: TLX) shares have been on fire this week.

    Despite the market weakness, the radiopharmaceuticals company’s shares have rocketed around 14% higher.

    The catalyst for this has been news that the company’s Pixclara product has been granted US FDA approval.

    So, should you be buying Telix shares as well because of this big news? Let’s find out what Bell Potter thinks.

    What is the broker saying?

    Bell Potter was pleased with the Pixclara news, highlighting that Telix is entering a new era with revenues set to jump in FY 2027. It said:

    The FDA’s approval of the new drug application for Pixclara (floretyrosine F18 aka FET-PET) heralds a new era for TLX, expanding its revenue base beyond the PSMA imaging. In fact, TLX now has multiple revenue streams inclusive of it is isotope manufacturing business, with FY27 revenues now likely to expand well beyond the US$1bn mark .

    Speaking about the product, the broker adds:

    The work now commences to execute on the commercialisation strategy commencing with the establishment of reimbursement and the appointment of radiopharmaceutical networks for distribution.

    We expect strong demand from the outset as FET-PET is the standard of care for the management of gliomas outside of the US. The drug has been available to a limited extent under the expanded access program in the US and there is a highly concentrated user group amongst radiation oncologists. The premium reimbursement relative to reimbursement on most other nuclear medicine exams will help prioritise FET-PET for machine time.

    Should you invest?

    According to the note, in response to the news, Bell Potter upgraded Telix shares to a buy rating with a $19.00 price target.

    Based on its current share price of $17.75, this implies potential upside of 7% for investors.

    Commenting on its investment thesis, it said:

    First revenues expected 2Q27. Revenues will be modest in the initial instance and not material to overall revenue growth in the short term. Despite this, the Pixclara approval is an important catalyst, particularly if the label expands to the larger brain metastases indication. We had previously included revenues from Pixclara in forecasts, hence no changes to earnings required. We upgrade our recommendation from Hold to Buy, PT $19.00.

    Overal, the broker appears to see potential for Telix shares to keep climbing in the near term. Though, the easy gains appear to be behind them.

    The post Are Telix shares a buy after its big US FDA news? appeared first on The Motley Fool Australia.

    Should you invest $1,000 in Telix Pharmaceuticals right now?

    Before you buy Telix Pharmaceuticals shares, consider this:

    Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Telix Pharmaceuticals wasn’t one of them.

    The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    And right now, Scott thinks there are 5 stocks that may be better buys…

    * Returns as of 1 August 2026

    .custom-cta-button p {
    margin-bottom: 0 !important;
    }

    More reading

    Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

  • James Hardie lifts guidance and details long-term growth at 2026 Investor Day

    Happy shareholders clap and smile as they listen to a company earnings report.

    The James Hardie Industries PLC (ASX: JHX) share price is in focus after the company hosted its 2026 Investor Day, where it reaffirmed guidance and raised its free cash flow target for FY27. Management highlighted the rapid progress on cost synergies and provided a strategic growth outlook.

    What did James Hardie report?

    • Targets annual organic growth of 4% to 7% above market, with compounding earnings
    • Expects to deliver US$125 million in cost synergies one year ahead of schedule
    • US$500 million in revenue synergies from the AZEK integration remain on track
    • Raised FY27 free cash flow target; reaffirmed FY27 net sales and Adjusted EBITDA guidance (excluding Europe)
    • Commits to capital allocation priorities, aiming to reduce net leverage to below 2.0x by Q2 FY28

    What else do investors need to know?

    James Hardie is accelerating the integration with AZEK, achieving faster-than-expected cost synergy targets. The company expects to complete the US$125 million cost synergy target a full year ahead of schedule, while revenue synergies are progressing as planned.

    The company is pressing ahead with the divestment of its European operations for about US$980 million. Proceeds are earmarked to pay down debt and fund share buybacks, which should support balance sheet strength and shareholder returns.

    What did James Hardie management say?

    Chief Executive Officer Aaron Erter said:

    We are also introducing our financial growth algorithm that outlines the building blocks to deliver 4% to 7% growth above market. This will be driven by a $23 billion material conversion opportunity, self-help growth initiatives, and $500 million in anticipated revenue synergies – all without underwriting a housing recovery.

    What’s next for James Hardie?

    James Hardie reaffirmed its FY27 sales and Adjusted EBITDA targets and lifted its free cash flow outlook, signalling confidence despite broader macroeconomic challenges. The company is prioritising organic growth, disciplined capital allocation—including debt reduction—and further bolt-on acquisitions.

    Management’s focus on compounding earnings and a robust North American growth strategy puts James Hardie on a path to deliver above-market returns, supported by structural drivers in the repair, remodel and new-build markets.

    James Hardie share price snapshot

    Over the past 12 months, James Hardie shares have risen 31%, outperforming the S&P/ASX 200 Index (ASX: XJO), which has declined 2% over the same period.

    View Original Announcement

    The post James Hardie lifts guidance and details long-term growth at 2026 Investor Day appeared first on The Motley Fool Australia.

    Should you invest $1,000 in James Hardie Industries Plc right now?

    Before you buy James Hardie Industries Plc shares, consider this:

    Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and James Hardie Industries Plc wasn’t one of them.

    The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    And right now, Scott thinks there are 5 stocks that may be better buys…

    * Returns as of 1 August 2026

    .custom-cta-button p {
    margin-bottom: 0 !important;
    }

    More reading

    Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

Sorry, but nothing was found. Please try a search with different keywords.